Manuscripts and Publications

Filters: Author is Doerschuk, Claire M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, C Davis W, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG et al..  2017.  Airway Mucin Concentration as a Marker of Chronic Bronchitis.. N Engl J Med. 377(10):911-922.
Martinez CH, Li SX, Hirzel AJ, Stolberg VR, Alexis NE, R Barr G, Bleecker ER, Carretta EE, Christenson SA, Cooper CB et al..  2018.  Alveolar eosinophilia in current smokers with chronic obstructive pulmonary disease in the SPIROMICS cohort.. J Allergy Clin Immunol. 141(1):429-432.
Putcha N, Fawzy A, Paul GG, Lambert AA, Psoter KJ, Sidhaye VK, Woo J, J Wells M, Labaki WW, Doerschuk CM et al..  2018.  Anemia and Adverse Outcomes in a Chronic Obstructive Pulmonary Disease Population with a High Burden of Comorbidities. An Analysis from SPIROMICS.. Ann Am Thorac Soc. 15(6):710-717.
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, R Barr G et al..  2017.  Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(12):956-967.
Burkes RM, Ceppe AS, Doerschuk CM, Couper D, Hoffman EA, Comellas AP, R Barr G, Krishnan JA, Cooper C, Labaki WW et al..  2020.  Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.. Chest. 157(4):856-865.
B
Keene JD, Jacobson S, Kechris K, Kinney GL, Foreman MG, Doerschuk CM, Make BJ, Curtis JL, Rennard SI, R Barr G et al..  2017.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.. Am J Respir Crit Care Med. 195(4):473-481.
C
W LeMaster B, P Quibrera M, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG et al..  2022.  Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.. Chest.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Sun W, Kechris K, Jacobson S, M Drummond B, Hawkins GA, Yang J, Chen T-H, Quibrera PMiguel, Anderson W, R Barr G et al..  2016.  Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.. PLoS Genet. 12(8):e1006011.
O'Neal WK, Anderson W, Basta PV, Carretta EE, Doerschuk CM, R Barr G, Bleecker ER, Christenson SA, Curtis JL, Han MK et al..  2014.  Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study.. J Transl Med. 12:9.
D
Freeman CM, Crudgington S, Stolberg VR, Brown JP, Sonstein J, Alexis NE, Doerschuk CM, Basta PV, Carretta EE, Couper DJ et al..  2015.  Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. J Transl Med. 13:19.
L
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
S
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
V
Anderson WH, Ha JWook, Couper DJ, O'Neal WK, R Barr G, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, M Drummond B et al..  2017.  Variability in objective and subjective measures affects baseline values in studies of patients with COPD.. PLoS One. 12(9):e0184606.